IP Library › Granted Patent US 12,404,554
Granted Patent B2
US 12,404,554 · App. 16/623,360 · Granted Sep 2, 2025

Methods and kits relating to the capture of CA-IX positive exosomes

Inventors: Antonio Chiesi (Siena, IT); Natasa Zarovni (Siena, IT); Davide Zocco (Siena, IT)
Assignee: EXOSOMICS S.P.A.
C12Q1/6886G01N33/54306C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,554
App. No.
16/623,360
Granted
Sep 2, 2025
Kind
B2
Abstract

Methods and kits for isolating tumour-derived exosomes by immunocapture with an anti CA-IX antibody, quantifying tumour-related nucleic acid sequences from the isolated exosomes and determining in vitro the presence of a tumour in a subject are provided.

Claims (8)

1. A method for in vitro quantification of a tumour-related nucleic acid sequence present in exosomes from a biological fluid, the method comprising:

a) capturing exosomes from a sample of said biological fluid with an anti CA-IX antibody, wherein the sample comprises exosomes having a detectable level of a tumour-related nucleic acid sequence; and

b) detecting a level of the tumour-related nucleic acid sequence present in the exosomes captured in step a) for in vitro quantification of the tumour-related nucleic acid sequence from said biological fluid, wherein the tumour-related nucleic acid sequence comprises a gene sequence from a target gene selected from the group consisting of: a BRAF gene, a KRAS gene, a HERV gene, a LINE gene, a c-Myc gene and an AR gene.

2. The method of claim 1 , wherein the exosomes are derived from a tumour selected from the group consisting of: lung cancer, breast cancer, bladder cancer, renal cancer, prostate cancer, colorectal cancer, gastric cancer, ovarian cancer and melanoma.

3. The method of claim 1 , wherein the tumour-related nucleic acid sequence is a wild-type sequence from the target gene.

4. The method of claim 1 , wherein the tumour-related nucleic acid sequence is a mutated sequence from the target gene.

5. The method of claim 4 , wherein the mutated sequence is selected from the group consisting of: an amplification, a point mutation, a deletion and an insertion.

6. The method of claim 1 , wherein the biological fluid is selected from the group consisting of: blood, plasma, serum, urine and saliva.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2020
From: CHIESI, ANTONIO; ZAROVNI, NATASA; ZOCCO, DAVIDE
To: EXOSOMICS S.P.A.
Reel/Frame 051574/0014 →
Priority Claims (1)
EP 17177190 · Jun 21, 2017 · regional
Continuity (1)
Related Publication 20200291482A1 · Sep 17, 2020
References Cited (27)
WO WO2011139375A1 · 2011 [cited by examiner]
WO 2012115885A1 · 2012 [cited by applicant]
WO 2015153732A2 · 2015 [cited by applicant]
Dorai, T. Glycobiology Insights 1:3-12. (Year: 2009). [cited by examiner]
International Search Report issued by the European Patent Office for corresponding Application No. PCT/EP2018/066604, dated Aug. 15, 2018, Rijswijk, Netherlands. [cited by applicant]
Chamie, et al.; “Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial”, Urologic Oncolog… [cited by applicant]
Pastorek, et al., “Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use”, Seminars in Cancer Biology, 2014, vol. 31, pp. 52-64, Elsevier Ltd. [cited by applicant]
Takacova, et al., “Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma”, Oncology Letters, 2013, vol. 5, Issue 1, pp. 191-197, Spandidos Publications. [cited by applicant]
Davies, H., et al., “Mutation of the BRAF gene in human cancer”, Letters to Nature, Jun. 27, 2002, vol. 417, pp. 949-954, Nature Publishing Group. [cited by applicant]
Corcoran, et al., “BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors In Cancer Cells Harboring The BRAF V600E Mutation”, Science Signaling, 2010, vol. 3, Issue 149, pp. 1-20, American Association… [cited by applicant]
Perincheri, et al. “KRAS Mutation testing in clinical practice”, Expert Review of Molecular Diagnostics, 2014, vol. 15, Issue 3, pp. 375-384, Informa UK Ltd. [cited by applicant]
Cercek, et al., “Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations”, Clinical Cancer Research, Aug. 15, 2017, vol. 23, Issue 16, pp. 4753-4760, American Association for Cancer R… [cited by applicant]
Mandalà, et al., “Nras in melanoma: Targeting the undruggable target”, Critical Reviews in Oncology/Hematology, 2014, vol. 92, Issue 2, pp. 107-122, Elsevier Ireland Ltd. [cited by applicant]
Passaro, et al., “Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment”, Pharmacological Research, 2017, vol. 117, pp. 406-415, Elsevier Ltd. [cited by applicant]
Fang, et al., “EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer”, Drug Design, Development and Therapy, 2014, vol. 8, pp. 1595-1611, Dove Medical Press Limited. [cited by applicant]
Gabay, et al., “MYC Activation Is a Hallmark of Cancer Initiation and Maintenance”, Cold Spring Harbor Perspective in Medicine, 2014, vol. 4(6), 4:a014241, Cold Spring Harbor Laboratory Press. [cited by applicant]
Balaj, et al., “Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences”, Nature Communications, Feb. 2011, 2:180, Macmillan Publishers Limited. [cited by applicant]
Romanel, et al., “Plasma AR and abiraterone-resistant prostate cancer”, Science Translational Medicine, Nov. 4, 2015, vol. 7, Issue 312, pp. 312re10, American Association for the Advancement of Science. [cited by applicant]
Antonarakis, et al., “AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer”, The New England Journal of Medicine, Sep. 11, 2014, vol. 371, No. 11, pp. 1028-1038, Massachusetts Medical Society. [cited by applicant]
Cheadle, et al., “Analysis of Microarray Data Using Z Score Transformation”, The Journal of Molecular Diagnostics, May 2003, vol. 5, Issue 2, pp. 73-81, American Society for Investigative Pathology and the Association f… [cited by applicant]
Tauro, et al., Two Distinct Populations of Exosomes Are Released from LIM1863 Colon Carcinoma Cell-derived Organoids, Molecular & Cellular Proteomics, Dec. 10, 2012, vol. 12, No. 3, pp. 587-598, The American Society for… [cited by applicant]
Zhang, et al., “Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: A novel vaccine for renal cell carcinoma”, International Journal Of Oncology, 2009, vol… [cited by applicant]
Abols, et al., “Carbonic anhydrase IX as the marker of the hypoxia induced extracellular vesicle secretion” (abstract p0368), United European Gastroenterology Journal, 2016, vol. 4, No. Supplement 5, p. A284. [cited by applicant]
Dorai, et al., “366 carbonic anhydrase IX shedding through exosomes in renal carcinoma cells”, The Journal of Urology, 2010, vol. 183, No. 4, p. e145. [cited by applicant]
Kalra, et al., “Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma”, Proteomics, 2013, vol. 13, No. 22, pp. 3354-3364, Wiley. [cited by applicant]
Written Opinion issued by the European Patent Office for corresponding Application No. PCT/EP2018/066604, dated Aug. 15, 2018, Rijswijk, Netherlands. [cited by applicant]
International Preliminary Report on Patentability issued by the European Patent Office for corresponding Application No. PCT/EP2018/066604, dated Dec. 24, 2019. [cited by applicant]